阿戈美拉汀治疗重度抑郁症。

文章的细节

引用

多尔德CR,尼尔森M,斯奈德M

阿戈美拉汀治疗重度抑郁症。

Ann Pharmacother. 2008年12月42(12):1822-31。doi: 10.1345 / aph.1L296。Epub 2008年11月25日。

PubMed ID
19033480 (查看PubMed
摘要

目的:综述阿戈美拉汀的疗效、安全性、药理学和药代动力学数据,以更好地了解其在治疗重度抑郁症患者中的潜在作用。资料来源:MEDLINE检索(1966- 200必威国际app8年10月)使用以下术语:阿戈美拉汀、抗抑郁药、S20098、褪黑素、血清素、5-羟色胺(2C)、MT、疗效、安全性、不良反应、药理学、药代动力学、受体结合、抑郁、重性抑郁障碍和情绪障碍。研究选择和数据提取:对从数据来源中识别的所有英文文章进行评估。该综述优先考虑了涉及人类的随机对照试验。还审查了在最初搜索过程中查明的已发表文章的参考资料,以确定是否有任何其他研究适合进行审查。必威国际app数据合成:Agomelatine, 1型和2型褪黑激素受体的强效激动剂,选择性地抑制血清素。它通过细胞色素P450同工酶1A1、1A2和2C9广泛代谢为代谢产物,其活性低于母体药物。五项随机对照研究确认了阿戈美拉汀治疗重度抑郁症的有效性和安全性。总体而言,与安慰剂相比,阿戈美拉汀在许多(但不是所有)评价量表上都能显著改善抑郁症状。其中3个试验有活跃的比较臂(即文拉法辛和帕罗西汀)。 In these 3 investigations, agomelatine produced effects on depressive symptoms similar to those of the comparator drugs. A small number of studies have demonstrated sleep benefits with the use of agomelatine in depressed patients. Positive findings also exist for the use of agomelatine in seasonal affective disorder and bipolar depression. The most common adverse effects reported with agomelatine use were headache, nasopharyngitis, and gastrointestinal complaints. The magnitude of agomelatine-related adverse effects appears to be at least similar to some currently marketed antidepressants. CONCLUSIONS: Overall, agomelatine is a promising and well-tolerated medication for the treatment of major depressive disorder. More large-scale controlled trials are needed to gain a better understanding of the relative efficacy and safety of agomelatine.

引用本文的药库数据

药物酶
药物 种类 生物 药理作用 行动
Agomelatine 细胞色素P450 2C9 蛋白质 人类
未知的
抑制剂
细节